IL283755A - Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors, compositions comprising same and uses thereof - Google Patents
Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors, compositions comprising same and uses thereofInfo
- Publication number
- IL283755A IL283755A IL283755A IL28375521A IL283755A IL 283755 A IL283755 A IL 283755A IL 283755 A IL283755 A IL 283755A IL 28375521 A IL28375521 A IL 28375521A IL 283755 A IL283755 A IL 283755A
- Authority
- IL
- Israel
- Prior art keywords
- atp
- compositions
- same
- protein kinase
- kinase inhibitors
- Prior art date
Links
- 230000003197 catalytic effect Effects 0.000 title 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 title 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776837P | 2018-12-07 | 2018-12-07 | |
| PCT/US2019/064960 WO2020118194A1 (en) | 2018-12-07 | 2019-12-06 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL283755A true IL283755A (en) | 2021-07-29 |
Family
ID=70974384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL283755A IL283755A (en) | 2018-12-07 | 2021-06-06 | Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors, compositions comprising same and uses thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US11078171B2 (enExample) |
| EP (2) | EP3890733B1 (enExample) |
| JP (2) | JP7594787B2 (enExample) |
| CN (1) | CN113395963B (enExample) |
| AU (3) | AU2019392904B9 (enExample) |
| CA (1) | CA3122371A1 (enExample) |
| ES (1) | ES3025468T3 (enExample) |
| IL (1) | IL283755A (enExample) |
| MX (2) | MX2021006731A (enExample) |
| WO (1) | WO2020118194A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7013453B2 (ja) | 2016-06-23 | 2022-01-31 | ユニバーシティ・オブ・メリーランド・ボルティモア | 内皮安定化及び抗炎症活性を有する非触媒基質選択的ｐ３８α特異的ＭＡＰＫ阻害剤、及びその使用方法 |
| JP7594787B2 (ja) | 2018-12-07 | 2024-12-05 | ユニバーシティ オブ メリーランド、ボルチモア | 非ＡＴＰ／触媒部位ｐ３８マイトジェン活性化プロテインキナーゼ阻害剤 |
| IL293965A (en) | 2019-12-19 | 2022-08-01 | Janssen Pharmaceutica Nv | History of Spiro straight chain transformed |
| IL298366A (en) | 2020-05-18 | 2023-01-01 | Gen1E Lifesciences Inc | P38 alpha mitogen-activated protein kinase inhibitors, compositions comprising same and uses thereof |
| JP2023546835A (ja) * | 2020-10-29 | 2023-11-08 | ジーニー ライフサイエンシズ インコーポレイテッド | 結晶性５－（ジメチルアミノ）－ｎ－（４－（モルホリノメチル）フェニル）ナフタレン－１－スルホンアミド二塩酸塩二水和物 |
| AU2022215844A1 (en) | 2021-02-02 | 2023-09-14 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
| IL306101A (en) * | 2021-03-23 | 2023-11-01 | Gen1E Lifesciences Inc | Naphthyl-mutated p38 alpha mitogen-activated protein kinase inhibitors |
| UY39681A (es) | 2021-03-26 | 2022-10-31 | Novartis Ag | Derivados de ciclobutilo 1,3–sustituidos y sus usos |
| WO2023111996A1 (en) | 2021-12-17 | 2023-06-22 | Reglagene Holding, Inc. | Compositions and methods of making and using small molecules in the treatment of cancer |
| IL321433A (en) | 2022-12-16 | 2025-08-01 | Astrazeneca Ab | Purines 2,6,9 trimethylated |
| US12215102B2 (en) | 2023-02-28 | 2025-02-04 | Reglagene, Inc. | Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions |
| CN116621794B (zh) * | 2023-05-22 | 2025-03-11 | 上海大学 | 一种5-苄基-2-氨基-1,3-噻唑类衍生物及其合成方法与应用 |
| US12116353B1 (en) * | 2024-04-25 | 2024-10-15 | Genie Lifesciences Inc. | Crystalline chloro-n-(4-(morpholinomethyl)phenyl)benzamide and crystalline hydrochloride salt |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR96352E (fr) | 1967-12-29 | 1972-06-16 | Science Union & Cie | Nouveaux dérives du spiro (4,5) decane et leur procédé de préparation. |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| DE19801646A1 (de) | 1998-01-17 | 1999-07-22 | Bayer Ag | Substituierte alpha,beta-annellierte Butyrolactone |
| JPH11269146A (ja) | 1998-03-24 | 1999-10-05 | Mitsui Chem Inc | 分化誘導剤 |
| CA2368047A1 (en) | 1999-03-24 | 2000-09-28 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds |
| PT1537116E (pt) * | 2002-09-04 | 2010-09-03 | Schering Corp | Pirazolopirimidinas adequadas para o tratamento de doenças cancerosas |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| EP1597259B1 (de) | 2003-02-13 | 2008-04-30 | Sanofi-Aventis Deutschland GmbH | Stickstoff substituierte hexahydro-pyrazino 1,2-a pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| US7297817B2 (en) | 2004-04-13 | 2007-11-20 | Cephalon France | Thio-substituted arylmethanesulfinyl derivatives |
| JP2007532615A (ja) * | 2004-04-13 | 2007-11-15 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| US7829560B2 (en) * | 2004-07-08 | 2010-11-09 | Arqule, Inc. | 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase |
| US20090299063A1 (en) | 2005-03-29 | 2009-12-03 | Paul Shapiro | Inhibitors for Extracellular Signal-Regulated Kinase Docking Domains and Uses Therefor |
| WO2008094319A2 (en) * | 2007-02-01 | 2008-08-07 | The Board Of Regents Of The University Of Texas Sytem | Methods and compositions of trail-death receptor agonists/activators |
| TW200904421A (en) | 2007-05-03 | 2009-02-01 | Astellas Pharma Inc | New compounds |
| ES2427892T3 (es) * | 2008-02-29 | 2013-11-04 | Chroma Therapeutics Limited | Inhibidores de MAP quinasa p38 |
| AU2009313315A1 (en) | 2008-11-07 | 2011-06-30 | The Cleveland Clinic Foundation | Compounds and methods of promoting oligodendrocyte precursor differentiation |
| WO2010082912A1 (en) | 2009-01-15 | 2010-07-22 | Avalon Pharmaceuticals | Derivatives of multi-ring aromatic compounds and uses as anti-tumor agents |
| UY32462A (es) | 2009-02-23 | 2010-09-30 | Arrow Therapeutics Ltd | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 |
| HUE065700T2 (hu) * | 2011-05-03 | 2024-06-28 | Agios Pharmaceuticals Inc | Piruvát-kináz aktivátorok terápiában történõ alkalmazásra |
| HK1217687A1 (zh) | 2013-01-15 | 2017-01-20 | Karl Alex MÜLLER | 利用紫外线辐射的氧化物的快速固态反应 |
| KR102283883B1 (ko) | 2013-04-02 | 2021-07-29 | 옥슬러 액퀴지션즈 리미티드 | 키나제 저해제 |
| US9025712B2 (en) | 2013-07-30 | 2015-05-05 | Pixart Imaging Inc. | Sensor, clock frequency adjusting system and method thereof |
| EP3076974A1 (en) * | 2013-12-05 | 2016-10-12 | Acerta Pharma B.V. | Therapeutic combination of a pi3k inhibitor and a btk inhibitor |
| US9447076B2 (en) | 2014-02-14 | 2016-09-20 | Respivert Ltd. | Inhibitor of p38 map kinase |
| CN113620958A (zh) * | 2014-03-19 | 2021-11-09 | 无限药品股份有限公司 | 用于治疗PI3K-γ介导的障碍的杂环化合物 |
| GB201417168D0 (en) | 2014-09-29 | 2014-11-12 | Univ Hertfordshire Higher Education Corp | Compounds |
| MA40775A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38 |
| JP2017538676A (ja) | 2014-11-05 | 2017-12-28 | ザ ユニバーシティ オブ カンザス | ミトコンドリア透過性遷移孔（ｍｔＰＴＰ）の小分子阻害剤 |
| US10858316B2 (en) * | 2015-07-10 | 2020-12-08 | University Of Maryland, Baltimore | Small molecule inhibitors of the MCL-1 oncoprotein and uses thereof |
| JP7013453B2 (ja) | 2016-06-23 | 2022-01-31 | ユニバーシティ・オブ・メリーランド・ボルティモア | 内皮安定化及び抗炎症活性を有する非触媒基質選択的ｐ３８α特異的ＭＡＰＫ阻害剤、及びその使用方法 |
| WO2018085348A1 (en) * | 2016-11-03 | 2018-05-11 | Actavalon, Inc. | Substituted quinolines and methods for treating cancer |
| TW201829381A (zh) | 2016-12-22 | 2018-08-16 | 美商拜奧馬林製藥公司 | 組蛋白脫乙醯基酶抑制劑 |
| KR20200104873A (ko) | 2017-12-06 | 2020-09-04 | 린 바이오사이언스, 피티와이 엘티디. | 튜불린 억제제 |
| JP7594787B2 (ja) * | 2018-12-07 | 2024-12-05 | ユニバーシティ オブ メリーランド、ボルチモア | 非ＡＴＰ／触媒部位ｐ３８マイトジェン活性化プロテインキナーゼ阻害剤 |
| WO2021183970A1 (en) | 2020-03-13 | 2021-09-16 | University Of Maryland, Baltimore | Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors |
| IL298366A (en) | 2020-05-18 | 2023-01-01 | Gen1E Lifesciences Inc | P38 alpha mitogen-activated protein kinase inhibitors, compositions comprising same and uses thereof |
| IL306101A (en) | 2021-03-23 | 2023-11-01 | Gen1E Lifesciences Inc | Naphthyl-mutated p38 alpha mitogen-activated protein kinase inhibitors |
-
2019
- 2019-12-06 JP JP2021532311A patent/JP7594787B2/ja active Active
- 2019-12-06 WO PCT/US2019/064960 patent/WO2020118194A1/en not_active Ceased
- 2019-12-06 MX MX2021006731A patent/MX2021006731A/es unknown
- 2019-12-06 CA CA3122371A patent/CA3122371A1/en active Pending
- 2019-12-06 ES ES19893204T patent/ES3025468T3/es active Active
- 2019-12-06 EP EP19893204.8A patent/EP3890733B1/en active Active
- 2019-12-06 AU AU2019392904A patent/AU2019392904B9/en active Active
- 2019-12-06 EP EP25161840.1A patent/EP4606792A1/en active Pending
- 2019-12-06 CN CN201980091398.5A patent/CN113395963B/zh active Active
-
2020
- 2020-05-11 US US16/872,114 patent/US11078171B2/en active Active
-
2021
- 2021-06-06 IL IL283755A patent/IL283755A/en unknown
- 2021-06-07 MX MX2024004162A patent/MX2024004162A/es unknown
- 2021-06-16 US US17/349,468 patent/US11718595B2/en active Active
-
2022
- 2022-11-04 AU AU2022263608A patent/AU2022263608B2/en active Active
-
2023
- 2023-04-26 JP JP2023072147A patent/JP2023106403A/ja active Pending
- 2023-06-07 US US18/206,925 patent/US12202810B2/en active Active
-
2024
- 2024-05-22 AU AU2024203398A patent/AU2024203398A1/en active Pending
- 2024-12-05 US US18/970,196 patent/US20250100985A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200331874A1 (en) | 2020-10-22 |
| US20250100985A1 (en) | 2025-03-27 |
| JP2023106403A (ja) | 2023-08-01 |
| AU2019392904A1 (en) | 2021-07-15 |
| MX2024004162A (es) | 2024-04-23 |
| CN113395963A (zh) | 2021-09-14 |
| EP3890733A4 (en) | 2022-05-04 |
| EP3890733B1 (en) | 2025-04-16 |
| EP3890733A1 (en) | 2021-10-13 |
| AU2019392904B2 (en) | 2022-08-25 |
| AU2019392904A2 (en) | 2021-08-26 |
| ES3025468T3 (en) | 2025-06-09 |
| US11078171B2 (en) | 2021-08-03 |
| EP3890733C0 (en) | 2025-04-16 |
| US20230312498A1 (en) | 2023-10-05 |
| JP7594787B2 (ja) | 2024-12-05 |
| WO2020118194A1 (en) | 2020-06-11 |
| CN113395963B (zh) | 2024-06-25 |
| MX2021006731A (es) | 2021-09-23 |
| AU2019392904B9 (en) | 2022-12-22 |
| AU2022263608A1 (en) | 2022-12-15 |
| CA3122371A1 (en) | 2020-06-11 |
| US20210317097A1 (en) | 2021-10-14 |
| US11718595B2 (en) | 2023-08-08 |
| AU2019392904A9 (en) | 2022-08-04 |
| US12202810B2 (en) | 2025-01-21 |
| AU2022263608B2 (en) | 2024-02-29 |
| JP2022511555A (ja) | 2022-01-31 |
| EP4606792A1 (en) | 2025-08-27 |
| NZ777458A (en) | 2024-03-22 |
| AU2024203398A1 (en) | 2024-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283755A (en) | Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors, compositions comprising same and uses thereof | |
| AU2022221446A1 (en) | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof | |
| IL283754A (en) | Anti-claudin antibodies, preparations containing them and their uses | |
| IL279015A (en) | Anti-interleukin-17A antibody, its pharmaceutical preparation and its use | |
| DK4122997T3 (da) | Stabiliserede fluorolefinsammensætninger og fremgangsmåder til fremstilling, oplagring og anvendelse deraf | |
| SG11202104687SA (en) | Ret inhibitors, pharmaceutical compositions and uses thereof | |
| IL268588A (en) | Anti-gprc5d antibodies, compositions comprising same and uses thereof | |
| IL276082B1 (en) | DNA-pk inhibitor compounds, preparations containing them and their uses | |
| IL276080A (en) | DNA-pk suppressor compounds, UTP-containing preparations and their uses | |
| IL285651A (en) | Anti-trem2 antibodies, preparations containing them and their uses | |
| IL275478A (en) | A preparation that functions as a bromodomain protein inhibitor, and the composition | |
| IL291299A (en) | Anti-TNFR2 antibodies, preparations containing them and their uses | |
| SG11202104686QA (en) | Ret inhibitors, pharmaceutical compositions and uses thereof | |
| DK3458020T3 (da) | Forbindelser til at fremme hårvækst og/eller at hæmme eller forsinke hårtab hos mennesker, og sammensætninger til sådanne anvendelser | |
| IL285595A (en) | Spt5 inhibitors and uses thereof | |
| SG11202101435XA (en) | ANTIBODY AGAINST IL-1ß, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| SG11202111012QA (en) | Trispecific binding proteins, methods, and uses thereof | |
| LT3587418T (lt) | Creb surišančio baltymo (cbp) inhibitoriai | |
| IL278701A (en) | Heterofused pyridones and their use as IDH inhibitors | |
| IL287435A (en) | Stable, low-viscosity antibody formulations and their uses | |
| SG11202011227VA (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
| EP3705121A4 (en) | EMOPAMIL BINDING PROTEIN BINDING AGENT AND ITS USE | |
| EP4061341A4 (en) | CASPASE 6 INHIBITORS AND THEIR USES | |
| IL273725A (en) | Peptides from Apanniadam10, preparations containing them and their uses | |
| ZA202104192B (en) | Mmpl3 inhibitors, compositions and uses thereof |